ASCO® 2024 Summary: "Gynecologic Oncology Updates"

2024 ASCO® Annual Meeting Insights Hub

R. Salani

ASCO® 2024 Summary: "Gynecological Cancers Highlights"

2024 ASCO® Annual Meeting Insights Hub

M. Raza Mirza

Gynecologic Oncology Updates: Expert Perspective on Key Trial Findin…

Yale Cancer Center

E. Ratner

ASCO® 2024 Summary: "Timing of Debulking Surgery in Advanced Endomet…

2024 ASCO® Annual Meeting Insights Hub

A. Karam

Management of Recurrent Ovarian Clear Cell Carcinoma

David Tan

Addressing the Critical Gaps in Relapsed Ovarian Cancer Management

Michael Birrer

Successful Carboplatin Desensitization Protocol in Gynecologic Cance…

Mariateresa Lapresa

Defining Platinum Resistance in Ovarian Cancer

Michael Birrer

2024 Updates in Ovarian Cancer

Total Health

T. Tillmanns

UChicago Medicine Best of ASCO® 2024: Options for Recurrent Platinum…

UChicago Medicine Annual Practice Updates in Hematology and Oncology

H. Cun

Precision Oncology in the Management of Ovarian Cancer

Miami Cancer Institute Precision Oncology Symposium

D. Dizon

ESMO 2024 Summary: Antibody Drug Conjugates (ADCs) - Identifying New…

2024 ESMO Annual Meeting Insights Hub

S. Banerjee

Overview of Ovarian Cancer Updates

Masonic Cancer Center, University of Minnesota

J. Mattson

Treatment Options for Platinum-Sensitive Recurrent Ovarian Cancer

Richard Penson

Genetic Testing in Determining Maintenance Treatment Options in Adva…

Alexander Olawaiye

Referral to Eye Care Provider for Management of Ocular Toxicity Asso…

Debra Richardson

ESGO 2024 Insights: "Antibody-Drug Conjugates in Ovarian Cancer"

Insights from 2024 ESGO Annual Meeting

J. Kurtz

ASCO® 2024 Insights: "CARACO Trial - Omission of Lymphadenectomy in …

2024 ASCO® Annual Meeting Insights Hub

J. Classe

Year in Review: Ovarian Cancer

Fengting Yan

SGO 2024 Insights: "Final OS Data of Relacorilant, a Selective Gluco…

Insights from 2024 SGO Annual Meeting

N. Colombo